Susanna J Dunachie

List of Publications by Year
in descending order

117 papers	35,036 citations	39113 52 h-index	27587 110 g-index
148 all docs	148 docs citations	148 times ranked	42556 citing authors

#	Article	IF	Citations
1	Co-evolutionary Signals IdentifyBurkholderia pseudomalleiSurvival Strategies in a Hostile Environment. Molecular Biology and Evolution, 2022, 39, .	3.5	10
2	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe, The, 2022, 3, e21-e31.	3.4	131
3	Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, The, 2022, 399, 629-655.	6.3	4,915
4	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	13.5	788
5	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 2022, 185, 916-938.e58.	13.5	164
6	SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2022, , ASN.2021121587.	3.0	4
7	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 2022, 13, 1251.	5.8	20
8	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	2.3	26
9	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	1.9	3
10	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut, 2022, 71, 1919.2-1922.	6.1	3
11	Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naÃ¯ve and convalescent healthcare workers. Clinical and Experimental Immunology, 2022, 209, 90-98.	1.1	5
12	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 2022, 185, 2116-2131.e18.	13.5	105
13	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7, .	2.3	24
14	Impaired humoral and cellular response to primary <scp>COVID</scp>â€19 vaccination in patients less than 2â€‰years after allogeneic bone marrow transplant. British Journal of Haematology, 2022, 198, 668-679.	1.2	13
15	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell, 2022, 185, 2422-2433.e13.	13.5	532
16	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 2022, 7, 1161-1179.	5.9	352
17	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
18	Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med, 2021, 2, 164-179.e12.	2.2	53

#	Article	IF	Citations
19	Mapping routine measles vaccination in low- and middle-income countries. Nature, 2021, 589, 415-419.	13.7	71
20	Role ofBurkholderia pseudomalleiâ€“Specific IgG2 in Adults with Acute Melioidosis, Thailand. Emerging Infectious Diseases, 2021, 27, 463-470.	2.0	13
21	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
22	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	5.8	54
23	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	5.8	102
24	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet, The, 2021, 397, 1459-1469.	6.3	557
25	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	13.5	936
26	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184, 2201-2211.e7.	13.5	442
27	COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet, The, 2021, 397, 1725-1735.	6.3	658
28	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	13.5	519
29	Equity for excellence in academic institutions: a manifesto for change. Wellcome Open Research, 2021, 6, 142.	0.9	6
30	Endemic HBV among hospital in-patients in Bangladesh, including evidence of occult infection. Journal of General Virology, 2021, 102, .	1.3	2
31	Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). Lancet Infectious Diseases, The, 2021, 21, 1677-1688.	4.6	50
32	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	2.1	190
33	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	13.5	630
34	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061.	5.8	150
35	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathogens, 2021, 17, e1009804.	2.1	39
36	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11.	13.5	262

#	Article	IF	Citations
37	The impact of viral mutations on recognition by SARS-CoV-2 specific TÂcells. IScience, 2021, 24, 103353.	1.9	57
38	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	1.3	46
39	Global antibiotic consumption and usage in humans, 2000â€“18: a spatial modelling study. Lancet Planetary Health, The, 2021, 5, e893-e904.	5.1	284
40	BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis. Frontiers in Immunology, 2021, 12, 767359.	2.2	6
41	Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC Medicine, 2020, 18, 1.	2.3	660
42	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	6.3	7,664
43	Melioidosis DS rapid test: A standardized serological dipstick assay with increased sensitivity and reliability due to multiplex detection. PLoS Neglected Tropical Diseases, 2020, 14, e0008452.	1.3	12
44	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
45	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
46	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology, 2020, 21, 1336-1345.	7.0	1,066
47	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infectious Diseases, The, 2020, 20, 1390-1400.	4.6	336
48	Serum From Melioidosis Survivors Diminished Intracellular Burkholderia pseudomallei Growth in Macrophages: A Brief Research Report. Frontiers in Cellular and Infection Microbiology, 2020, 10, 442.	1.8	11
49	The challenges of estimating the human global burden of disease of antimicrobial resistant bacteria. Current Opinion in Microbiology, 2020, 57, 95-101.	2.3	45
50	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000â€“17: analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 1779-1801.	6.3	72
51	Human Immune Responses to Melioidosis and Cross-Reactivity to Low-Virulence Burkholderia Species, Thailand1. Emerging Infectious Diseases, 2020, 26, 463-471.	2.0	15
52	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. Nature Medicine, 2020, 26, 750-759.	15.2	47
53	Automating the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in Seven Countries. Journal of Medical Internet Research, 2020, 22, e19762.	2.1	14
54	Global antibiotic consumption: A modelling study. International Journal of Infectious Diseases, 2020, 101, 91.	1.5	0

#	Article	IF	Citations
55	Travel and expedition medicine. , 2020, , 713-722.		0
56	Improving the estimation of the global burden of antimicrobial resistant infections. Lancet Infectious Diseases, The, 2019, 19, e392-e398.	4.6	68
57	The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infectious Diseases, The, 2019, 19, 1312-1324.	4.6	338
58	Diabetes alters immune response patterns to acute melioidosis in humans. European Journal of Immunology, 2019, 49, 1092-1106.	1.6	39
59	Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. BMC Medicine, 2019, 17, 70.	2.3	55
60	The double burden of diabetes and global infection in low and middle-income countries. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 56-64.	0.7	105
61	Human MAIT cells show metabolic quiescence with rapid glucoseâ€dependent upregulation of granzyme B upon stimulation. Immunology and Cell Biology, 2018, 96, 666-674.	1.0	34
62	The association between temperature, rainfall and humidity with common climate-sensitive infectious diseases in Bangladesh. PLoS ONE, 2018, 13, e0199579.	1.1	89
63	Melioidosis in Thailand: Present and Future. Tropical Medicine and Infectious Disease, 2018, 3, 38.	0.9	58
64	Melioidosis in Bangladesh: A Clinical and Epidemiological Analysis of Culture-Confirmed Cases. Tropical Medicine and Infectious Disease, 2018, 3, 40.	0.9	12
65	Characterization of the rhesus macaque (Macaca mulatta) scrub typhus model: Susceptibility to intradermal challenge with the human pathogen Orientia tsutsugamushi Karp. PLoS Neglected Tropical Diseases, 2018, 12, e0006305.	1.3	9
66	Immune response to recombinant Burkholderia pseudomallei FliC. PLoS ONE, 2018, 13, e0198906.	1.1	23
67	Smartphones for community health in rural Cambodia: A feasibility study. Wellcome Open Research, 2018, 3, 69.	0.9	8
68	Antibodies in Melioidosis: The Role of the Indirect Hemagglutination Assay in Evaluating Patients and Exposed Populations. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1378-1385.	0.6	33
69	Pandemics, pathogenicity and changing molecular epidemiology of cholera in the era of global warming. Annals of Clinical Microbiology and Antimicrobials, 2017, 16, 10.	1.7	86
70	Infection with Burkholderia pseudomallei â€“ immune correlates of survival in acute melioidosis. Scientific Reports, 2017, 7, 12143.	1.6	42
71	Comparison of O-polysaccharide and hemolysin co-regulated protein as target antigens for serodiagnosis of melioidosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005499.	1.3	46
72	A nonsense mutation in TLR5 is associated with survival and reduced IL-10 and TNF-Î± levels in human melioidosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005587.	1.3	16

#	Article	IF	Citations
73	Strong interferon-gamma mediated cellular immunity to scrub typhus demonstrated using a novel whole cell antigen ELISpot assay in rhesus macaques and humans. PLoS Neglected Tropical Diseases, 2017, 11, e0005846.	1.3	11
74	Clinical Epidemiology of Septic Arthritis Caused by Burkholderia pseudomallei and Other Bacterial Pathogens in Northeast Thailand. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1695-1701.	0.6	10
75	Rapid and Sensitive Multiplex Detection of Burkholderia pseudomallei-Specific Antibodies in Melioidosis Patients Based on a Protein Microarray Approach. PLoS Neglected Tropical Diseases, 2016, 10, e0004847.	1.3	30
76	Characterization of the Specificity, Functionality, and Durability of Host Tâ€Cell Responses Against the Fullâ€Length Hepatitis E Virus. Hepatology, 2016, 64, 1934-1950.	3.6	42
77	Acquisition and Longevity of Antibodies to Plasmodium vivax Preerythrocytic Antigens in Western Thailand. Vaccine Journal, 2016, 23, 117-124.	3.2	42
78	Burkholderia pseudomallei induces IL-23 production in primary human monocytes. Medical Microbiology and Immunology, 2016, 205, 255-260.	2.6	9
79	Association between Subclinical Malaria Infection and Inflammatory Host Response in a Pre-Elimination Setting. PLoS ONE, 2016, 11, e0158656.	1.1	13
80	Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia. BMC Infectious Diseases, 2015, 15, 511.	1.3	103
81	Consensus on the Development of Vaccines against Naturally Acquired Melioidosis. Emerging Infectious Diseases, 2015, 21, .	2.0	57
82	Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model. Vaccine, 2015, 33, 5321-5331.	1.7	35
83	Profiling the host response to malaria vaccination and malaria challenge. Vaccine, 2015, 33, 5316-5320.	1.7	21
84	T Cell Immunity to the Alkyl Hydroperoxide Reductase of Burkholderia pseudomallei: A Correlate of Disease Outcome in Acute Melioidosis. Journal of Immunology, 2015, 194, 4814-4824.	0.4	44
85	T-Cell Responses Are Associated with Survival in Acute Melioidosis Patients. PLoS Neglected Tropical Diseases, 2015, 9, e0004152.	1.3	69
86	Radiological features do not predict failure of two-stage arthroplasty for prosthetic joint infection: a retrospective caseâ€“control study. BMC Musculoskeletal Disorders, 2014, 15, 300.	0.8	1
87	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. Journal of Infectious Diseases, 2013, 208, 340-345.	1.9	53
88	Host Responses to Melioidosis and Tuberculosis Are Both Dominated by Interferon-Mediated Signaling. PLoS ONE, 2013, 8, e54961.	1.1	55
89	Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B₁₂vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors. JAMA - Journal of the American Medical Association, 2010, 303, 2486.	3.8	283
90	MIG and the Regulatory Cytokines IL-10 and TGF-Î²1 Correlate with Malaria Vaccine Immunogenicity and Efficacy. PLoS ONE, 2010, 5, e12557.	1.1	16

#	Article	IF	Citations
91	Quantitative PCR Evaluation of Cellular Immune Responses in Kenyan Children Vaccinated with a Candidate Malaria Vaccine. PLoS ONE, 2009, 4, e8434.	1.1	8
92	Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 65-72.	0.9	59
93	MIG (CXCL9) is a more sensitive measure than IFN-Î³ of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines. Journal of Immunological Methods, 2009, 340, 33-41.	0.6	26
94	Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-Î²1. Vaccine, 2008, 26, 5269-5275.	1.7	23
95	Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. PLoS ONE, 2008, 3, e1493.	1.1	99
96	A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine, 2006, 24, 2850-2859.	1.7	86
97	Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. Infection and Immunity, 2006, 74, 2706-2716.	1.0	62
98	A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge. Infection and Immunity, 2006, 74, 5933-5942.	1.0	154
99	Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naiˆve and Malaria-Exposed Individuals. Infection and Immunity, 2006, 74, 6331-6338.	1.0	22
100	Calculation of Liverâ€toâ€Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. Journal of Infectious Diseases, 2005, 191, 619-626.	1.9	152
101	Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers. Journal of Immunology, 2005, 174, 449-455.	0.4	143
102	Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. Journal of Immunology, 2005, 175, 5675-5680.	0.4	123
103	Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4836-4841.	3.3	228
104	Upregulation of TGF-Î², FOXP3, and CD4+CD25+ Regulatory T Cells Correlates with More Rapid Parasite Growth in Human Malaria Infection. Immunity, 2005, 23, 287-296.	6.6	328
105	Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine, 2005, 23, 857-864.	1.7	72
106	QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-198.	0.6	96
107	Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-8.	0.6	71
108	Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine, 2003, 9, 729-735.	15.2	536

#	Article	IF	Citations
109	Prime-boost strategies for malaria vaccine development. Journal of Experimental Biology, 2003, 206, 3771-3779.	0.8	89
110	Snake bites in Kenya: a preliminary survey of four areas. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 319-321.	0.7	22
111	Fatal COVID-19 Outcomes are Associated with an Antibody Response Targeting Epitopes Shared with Endemic Coronaviruses. SSRN Electronic Journal, 0, , .	0.4	3
112	The Impact of Viral Mutations on Recognition by SARS-CoV-2 Specific T-Cells. SSRN Electronic Journal, 0, , .	0.4	11
113	Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection. SSRN Electronic Journal, 0, , .	0.4	6
114	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. SSRN Electronic Journal, 0, , .	0.4	2
115	Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity â€“ The OCTAVE Trial. SSRN Electronic Journal, 0, , .	0.4	51
116	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	15
117	Global Antibiotic Consumption in Humans, 2000 to 2018: A Spatial Modelling Study. SSRN Electronic Journal, 0, , .	0.4	0